Standard BioTools Stock

Standard BioTools Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Standard BioTools (LAB) as of Aug 6, 2026 is 124.32. In the previous year, Cash Conversion Cycle (CCC) was 115.18 — a change of 7.93% (higher).

Cash Conversion Cycle

124.32

YoY

7.93%

Last updated:

Cash Conversion Cycle (CCC) of Standard BioTools is 2026 124.32 . Cash Conversion Cycle (CCC) of Standard BioTools was 2025 115.18 . It decreases by 7.93% higher compared to the previous year.
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Cash Conversion Cycle (CCC) of Standard BioTools is 124.32 in 2026.

Cash Conversion Cycle (CCC) of Standard BioTools changed from 115.18 to 124.32, representing a 7.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Standard BioTools with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Standard BioTools

All Key Metrics — Standard BioTools